Skip to main content
Explore URMC

Wilmot Cancer Institute Logo

menu
Jason H. Mendler, M.D., Ph.D.
Jason H. Mendler, M.D., Ph.D.

Jason H. Mendler, M.D., Ph.D.

Medicine — Hematology/Oncology — Internal Medicine

Accepting New Patients

Jason H. Mendler, M.D., Ph.D.

Medicine — Hematology/Oncology — Internal Medicine

Accepting New Patients


Locations

James P. Wilmot Cancer Center
601 Elmwood Ave.
Rochester, NY 14642
Get Directions

phone

Appointments

(585) 275-5823

print

Fax

(585) 273-1051

About Me

I chose oncology because of its richness and the ability to impact people's lives in a positive way. The field is unmatched in terms of the interpersonal relationships that are developed, medical complexity and research opportunities.

My philosophy is that optimal patient care stems from both a thorough understanding of the disease process, as well as intimate knowledge of the patient as a human being. I continually work to deepen my relationships with patients in order to improve outcomes.

I am a regular person who is as comfortable coaching my kids' sports teams as I am with a stethoscope around my neck. I love spending time with my family, which includes my wife Ticia and children Caleb, Ava and Megan. My area of expertise includes myeloid leukemias.

Conditions I Treat

- Acute leukemia, all types
- Chronic myeloid leukemia
- Myelodysplastic syndrome
- Myeloproliferative disorders including polycythemia vera, myelofibrosis and essential thrombocythemia

Credentials

Education:

MD | University of Rochester School of Medicine & Dentistry — 2005
PhD | University of Rochester School of Medicine & Dentistry — 2004

Post-doctoral Training & Residency:

Residency in Internal Medicine at University of Rochester Medical Center — 2006 - 2008
Internship in Internal Medicine at University of Rochester Medical Center — 2005 - 2006
Fellowship in Medical Oncology at Ohio State University Medical Center — 2009 - 2011

Research

Publications:

Khalife J, Radomska HS, Santhanam R, Huang X, Neviani P, Saultz J, Wang H, Wu YZ, Alachkar H, Anghelina M, Dorrance A, Curfman J, Bloomfield CD, Medeiros BC, Perrotti D, Lee LJ, Lee RJ, Caligiuri MA, Pichiorri F, Croce CM, Garzon R, Guzman ML, Mendler JH, Marcucci G. "Pharmacological targeting of miR-155 via the NEDD8-activating enzyme inhibitor MLN4924 (Pevonedistat) in FLT3-ITD acute myeloid leukemia." Leukemia.. 2015 Oct 0; 29(10):1981-92. Epub 2015 May 14.

Niederwieser C, Kohlschmidt J, Volinia S, Whitman SP, Metzeler KH, Eisfeld AK, Maharry K, Yan P, Frankhouser D, Becker H, Schwind S, Carroll AJ, Nicolet D, Mendler JH, Curfman JP, Wu YZ, Baer MR, Powell BL, Kolitz JE, Moore JO, Carter TH, Bundschuh R, Larson RA, Stone RM, Mrózek K, Marcucci G, Bloomfield CD. "Prognostic and biologic significance of DNMT3B expression in older patients with cytogenetically normal primary acute myeloid leukemia." Leukemia.. 2015 Mar 0; 29(3):567-75. Epub 2014 Sep 10.

Sivagnanalingam U, Balys M, Eberhardt A, Wang N, Myers JR, Ashton JM, Becker MW, Calvi LM, Mendler JH. "Residual Disease in a Novel Xenograft Model of RUNX1-Mutated, Cytogenetically Normal Acute Myeloid Leukemia." PloS one. 2015 10(7):e0132375. Epub 2015 Jul 15.

View All Publications